New investigator-initiated research could help revive Pfizer's acute myeloid leukaemia (AML) treatment, Mylotarg (gemtuzumab ozogamicin), following the withdrawal of the product last year.
New investigator-initiated research could help revive Pfizer's acute myeloid leukaemia (AML) treatment, Mylotarg (gemtuzumab ozogamicin), following the withdrawal of the product last year.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.
